Finally TGA has registered Mifepristone Linepharma (RU 486) and GyMiso (misoprostol) on Australian Register of Therapeutic Goods. These drugs are for aborting pregnancy that is taking place within the uterus.
It has been reported that 200mg tablet of RU 486 has been registered, which is to be given along with a prostaglandin analogue up to seven to nine weeks of gestation. TGA declared the registration yesterday.
A spokesman for Marie Stopes International Australia asserted that they had set up a health subsidiary, MS Health, which will be focusing on health concerns, instead of making profits. This health subsidiary has been introduced to market and distribute health products related to pregnancy and reproduction.
Moreover, they have drafted certain educational packages, which they will be providing with the medicines. However, the packages have been developed for only those recommending the Mifepristone Linepharma.
Although the drug was available in Australia since the past six year, it was sold under strict rules and conditions. However, with the registration of the drug, more of the Australian women will be able to have it.
Gynecologist Caroline de Costa said, “The drug should have been registered earlier. The way surgical abortion is and it should have been seen as a health issue for women”.
Good News USA
- Vodafone NZ’s new ‘Red Home’ packages will offer UFB and 150 TV channels
- Vodafone NZ’s full-year profit plunged by more than two-thirds to $56 million
- Vodafone adding 34 European countries to ‘AU$5 per day’ international roaming option
- Telstra launches its new ‘Every Day Connect Data Share Packages’
- Voyager signs “multimillion-dollar deal” with submarine cable group Hawaiki